Minimum inhibitory concentration

CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, Pipeline, and Potential Near-Term Catalysts

Monday, September 13, 2021 - 2:48pm

Acurx Pharmaceutical's CEO tells Soulstring Media why he thinks 2021-22 can be a breakout year for his company

Key Points: 
  • Rather than speculate on each drug's market potential, HPM reached out to Mr. David Luci, CEO of Acurx, allowing him to respond to investor questions.
  • Acurx is outside that mold because we have a new class of antibiotics treating life-threatening infections with two in the class.
  • Our scientific team has indicated publicly that these data portend future success in Phase 2b and Phase 3.
  • Q: The Phase 2b trial can be transformative to Acurx, especially if data proves superior to standard of care Vancomycin in the imminent head-to-head match-up.

CEO Spotlight: Acurx Pharmaceuticals in Focus with CEO David Luci Talking Potentially Transformative Phase 2b Trial, Pipeline, and Potential Near-Term Catalysts

Monday, September 13, 2021 - 1:03pm

Acurx Pharmaceutical's CEO tells Soulstring Media why he thinks 2021-22 can be a breakout year for his company

Key Points: 
  • Rather than speculate on each drug's market potential, HPM reached out to Mr. David Luci, CEO of Acurx, allowing him to respond to investor questions.
  • Acurx is outside that mold because we have a new class of antibiotics treating life-threatening infections with two in the class.
  • Our scientific team has indicated publicly that these data portend future success in Phase 2b and Phase 3.
  • Q: The Phase 2b trial can be transformative to Acurx, especially if data proves superior to standard of care Vancomycin in the imminent head-to-head match-up.

Global Antimicrobial Susceptibility Test Market Outlook (2019 to 2027) - Featuring Biotron Healthcare, Conda & Creative Diagnostics Among Others - ResearchAndMarkets.com

Friday, June 26, 2020 - 1:50pm

The "Antimicrobial Susceptibility Test - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Antimicrobial Susceptibility Test - Global Market Outlook (2019-2027)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Antimicrobial Susceptibility Test market accounted for $2.79 billion in 2019 and is expected to reach $4.98 billion by 2027 growing at a CAGR of 7.5% during the forecast period.
  • To examine the antimicrobial susceptibility, the most widely used testing methods are broth microdilution or rapid automated instrument methods.
  • The rising prevalence of antimicrobial resistance in North America is another key factor supporting the expansion of this regional segment in the global antimicrobial susceptibility testing market.

Tetraphase Pharmaceuticals to Present Data at the 22nd Annual MAD-ID Meeting

Thursday, May 2, 2019 - 12:00pm

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced five data presentations at the 22nd Annual MAD-ID (Making a Difference in Infectious Diseases) Meeting, taking place May 8-11, 2019 in Orlando, Fla.

Key Points: 
  • Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel tetracyclines to treat serious and life-threatening conditions, today announced five data presentations at the 22nd Annual MAD-ID (Making a Difference in Infectious Diseases) Meeting, taking place May 8-11, 2019 in Orlando, Fla.
  • The details for the data presentations at MAD-ID are as follows:
    Date and time: Thursday, May 9 from 5:00 6:30 p.m.
  • ET
    Poster title: Multi-Site Evaluation of Eravacycline MIC Test Strip Compared to Broth Microdilution for Enterobacteriaceae, S. aureus and Enterococcus spp.
  • To report SUSPECTED ADVERSE REACTIONS, contact Tetraphase Pharmaceuticals Inc., at 1-833-7-XERAVA (1-833-793-7282) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .